Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice.

Sajjad Afraz, Ivan Stevic, Davide Matino, Jianping Wen, Helen Atkinson, Anthony K C Chan, Gonzalo Hortelano

Abstract read

In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sajjad AfrazThrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada.

Ivan StevicDepartment of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.

Davide MatinoThrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada.

Jianping WenMcMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.

Helen AtkinsonThrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada.

Anthony K C ChanThrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada.

Gonzalo HortelanoSchool of Biomedical Engineering, McMaster University, Hamilton, ON, Canada. gonzalo.hortelano@NU.edu.kz.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemophilia A is an X-linked recessive congenital bleeding disorder. Exogenous infusion of FVIII is the treatment of choice, and the development of immunoglobulins against FVIII (inhibitors) remains the major challenge in clinical management of the disease. Here, we investigated the effect of co-administration of FVIII with intravenous immunoglobulin (IVIG) on the development of inhibitors in previously untreated hemophilia A mice. A group of hemophilia A mice (C57BL/6

Indexed as

Hemophilia AAnimalsAntibodiesFactor VIIIHumansImmunityImmunoglobulins, IntravenousMiceMice, Inbred C57BLAntibodiesFactor VIIIImmunoglobulins, Intravenous

Identifiers

PMID36418333

DOI10.1038/s41598-022-19392-1

PMCPMC9684572

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.